2134169-43-8

MI-3454 induces complete remission or regression of leukemia in mouse models of mixed lineage leukemia 1 (MLL1)-rearranged or nucleophosmin 1 (NPM1)-mutated leukemia^[1].
? MI-3454 (p.o.; 120 mg/kg; one or twice daily for 7 consecutive days) sufficiently blocks leukemia progression by a once-daily treatment^[1].
? MI-3454 (p.o.; 100 mg/kg; b.i.d.; for 19 consecutive days) effectively blocks leukemia progression during the treatment period and markedly prolongs survival of MOLM13 xenotransplantation model mice. MI-3454 induces complete remission or blocks leukemia progression in patient-derived xenograft (PDX) models of MLL leukemia^[1].
? MI-3454 (100 mg/kg of PO or 15 mg/kg of IV) has a T_1/2 of 3.2 hours, a C_max of 4698 mg/mL for PO^[1].
? MI-3454 exhibits favorable stability in murine and human liver microsomes (t_1/2=20.4 minutes and 37.1 minutes, respectively)^[1].
? MI-3454 demonstrates lower levels in brain and cerebrospinal fluid, suggesting limited ability to cross the blood-brain barrier^[1].